Beyond Air (NASDAQ:XAIR) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Beyond Air (NASDAQ:XAIR) in a research note published on Wednesday,Benzinga reports. D. Boral Capital currently has a $10.00 target price on the stock.

Several other equities research analysts have also commented on XAIR. Weiss Ratings restated a “sell (e)” rating on shares of Beyond Air in a research note on Monday, December 22nd. Wall Street Zen upgraded Beyond Air to a “sell” rating in a research report on Saturday, March 7th. Finally, Rodman & Renshaw assumed coverage on Beyond Air in a research report on Tuesday, January 20th. They issued a “buy” rating on the stock. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Beyond Air Stock Performance

Shares of NASDAQ XAIR opened at $0.81 on Wednesday. The company has a quick ratio of 4.77, a current ratio of 5.12 and a debt-to-equity ratio of 2.65. The firm’s 50-day moving average price is $1.15 and its two-hundred day moving average price is $1.54. Beyond Air has a 52-week low of $0.67 and a 52-week high of $6.39. The stock has a market capitalization of $8.50 million, a P/E ratio of -0.15 and a beta of 0.41.

Beyond Air (NASDAQ:XAIR) last announced its quarterly earnings results on Friday, February 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.31). The company had revenue of $2.19 million for the quarter, compared to analyst estimates of $2.15 million. Beyond Air had a negative return on equity of 268.82% and a negative net margin of 447.75%. As a group, sell-side analysts forecast that Beyond Air will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Beyond Air

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alpine Global Management LLC acquired a new stake in shares of Beyond Air in the third quarter valued at $25,000. Osaic Holdings Inc. grew its holdings in Beyond Air by 26.4% during the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after acquiring an additional 34,000 shares during the period. Virtu Financial LLC acquired a new position in Beyond Air during the third quarter worth about $48,000. Geode Capital Management LLC raised its position in Beyond Air by 57.5% in the fourth quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock worth $49,000 after acquiring an additional 24,695 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in Beyond Air in the third quarter worth about $1,753,000. 31.50% of the stock is owned by institutional investors.

About Beyond Air

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.